Screen More. Find More. Save More.
The Unscreened Don’t Benefit From an Unused Test
Every year 1 in 3 age eligible Americans goes unscreened for colorectal cancer.
Take-home stool tests have low compliance rates that leave many unscreened. In a clinical study, the FDA-approved Epi proColon blood test has demonstrated a compliance rate of 99.5%. Unscreened patients with colorectal cancer tend to be diagnosed in later stages when symptoms exhibit. Screening the unscreened leads to early cancer detection and prevention by polyp/lesion removal, resulting a reduction in healthcare costs.
|Epi proColon Blood Test||99.5%|
*References available upon request
In the unscreened population, Epi proColon will screen more people, detect more cancers/lesions, and make a great addition to your colon cancer screening program. If 10,000 patients are offered the different testing options, these are the expected outcomes:
Find out how Epi proColon can screen more people, save lives, and reduce healthcare dollars.